Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.
Diagnosis of KSHV-infected individuals remains a challenge. KSHV prevalence is high in several populations with high prevalence of HIV, leading to increased risk of development of Kaposi's sarcoma (KS). While current assays are reliable for detecting antibodies to KSHV, none are routinely utilized to identify individuals with KSHV infection and thus at increased risk for KS due to assay complexity, lack of access to testing, and cost, particularly in resource-limited settings. Here we describe the addition of KSHV proteins LANA and K8.1 to a previously evaluated HIV/co-infection multiplexed fluorescence immunoassay system. This study demonstrates assay performance by measuring antibody reactivity for KSHV and HIV-1 in a collection of clinical specimens from patients with biopsy-proven KS and sourced negative controls. The KSHV assay correctly identified 155 of 164 plasma samples from patients with biopsy-proven KS and 85 of 93 KSHV antibody (Ab)-negative samples for a sensitivity of 95.1% and specificity of 91.4%. Assay performance for HIV-1 detection was also assessed with 100% agreement with independently verified HIV-1 Ab-positive and Ab-negative samples. These results demonstrate good sensitivity and specificity for detection of antibody to KSHV antigens, and demonstrate the potential for multiplexed co-infection testing in resource-limited settings to identify those at increased risk for HIV-1-related complications.
Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA, United States of America.
Cathy
C
Logan
MBio Diagnostics, Inc., Boulder, CO, United States of America.
Kathryn
K
Todorof
Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, CO, United States of America.
Suzanne P
SP
Fiorillo
Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, CO, United States of America.
Thomas B
TB
Campbell
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, United States of America.
John H
JH
Elder
Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Margaret
M
Borok
Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Ivy
I
Gudza
Departments of Medicine and Medical and Laboratory Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Lovemore
L
Gwanzura
Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Buxton
B
Ndemera
MBio Diagnostics, Inc., Boulder, CO, United States of America.
Michael J
MJ
Lochhead
Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA, United States of America.
Constance A
CA
Benson
Department of Medicine, Division of Infectious Diseases, University of California San Diego, San Diego, CA, United States of America.
Robert T
RT
Schooley
Int J Cancer. 2015 Jun 15;136(12):2822-30
25395177
N Engl J Med. 1996 May 16;334(20):1292-7
8609946
Infect Agent Cancer. 2011 Nov 17;6:22
22093140
Br J Cancer. 2006 May 22;94(10):1504-9
16705315
Clin Infect Dis. 2010 Aug 1;51(3):342-9
20572760
AIDS. 2008 May 31;22(9):1019-28
18520345
J Clin Microbiol. 2007 Mar;45(3):715-20
17182752
Lancet. 1995 Mar 25;345(8952):759-61
7891487
Infect Agent Cancer. 2010 Aug 31;5:14
20807396
Transfusion. 2003 Jan;43(1):85-90
12519435
J Virol. 2002 Mar;76(6):2634-40
11861829
Int J Cancer. 2013 Aug 1;133(3):721-9
23364833
Virology. 1999 Apr 10;256(2):381-92
10191203
Sao Paulo Med J. 2015 Apr 14;134(3):187-92
25885486
N Engl J Med. 1995 May 4;332(18):1186-91
7700311
Br J Cancer. 2011 Nov 22;105(11):1768-71
21952625
Virol Sin. 2010 Jun;25(3):168-76
20960290
J Virol. 2004 Nov;78(21):11707-14
15479812
HIV Med. 2016 Jan;17 (1):56-61
26111246
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):346-54
10836758
Annu Rev Pathol. 2006;1:273-96
18039116
Transfusion. 2003 Sep;43(9):1260-8
12919429
Clin Vaccine Immunol. 2009 May;16(5):621-7
19261774
J Immunol Methods. 2010 Apr 30;356(1-2):39-46
20211626
Int J Cancer. 2013 Sep 1;133(5):1197-203
23436712
Lancet. 1995 Sep 23;346(8978):799-802
7674745
Science. 1994 Dec 16;266(5192):1865-9
7997879
Blood. 1995 Aug 15;86(4):1276-80
7632932
J Infect Dis. 2010 Jun 15;201(12):1919-22
20443737
PLoS Pathog. 2014 Mar 27;10(3):e1004046
24675986
J Infect Dis. 1998 Aug;178(2):304-9
9697708
Nat Med. 1996 Aug;2(8):925-8
8705864
Transfusion. 2003 Dec;43(12):1764-5
14674378
Nat Rev Immunol. 2007 May;7(5):391-401
17457345
J Clin Microbiol. 2002 Feb;40(2):325-9
11825937
Cancer Sci. 2011 Oct;102(10):1769-73
21740480
Transfusion. 2008 Jun;48(6):1180-7
18422852
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):83-90
21084997
J Med Virol. 2013 Sep;85(9):1602-10
23852686
Virology. 2000 Apr 10;269(2):335-44
10753712
Blood. 1998 Jul 1;92(1):53-8
9639499
J Clin Microbiol. 2006 Oct;44(10):3734-41
17021103
J Virol. 1996 Jan;70(1):549-58
8523568
PLoS One. 2013 Aug 14;8(8):e71254
23967174
J Infect Dis. 2011 Dec 1;204(11):1683-91
21990424
PLoS One. 2011;6(8):e23546
21858163
Curr Opin Oncol. 2012 Sep;24(5):522-30
22729153
J Clin Microbiol. 2011 Oct;49(10):3584-90
21865431
Nat Med. 1996 Aug;2(8):918-24
8705863
J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41
10430217
J Infect Dis. 2007 Jul 15;196(2):208-11
17570107
Lancet. 1996 Oct 26;348(9035):1133-8
8888167
J Clin Microbiol. 2000 Feb;38(2):696-701
10655369
Clin Infect Dis. 2003 May 1;36(9):1144-51
12715309
Lancet. 1995 Apr 22;345(8956):1043-4
7723505